



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy

Phone 503-947-5220 | Fax 503-947-1119

## Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, April 4<sup>th</sup>, 2024

1:05 PM - 4:45 PM

Via Zoom webinar

### MEETING MINUTES

---

**NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333**

**Members Present:** Bridget Bradley, PharmD; Douglas Carr, MD; Russ Huffman, PMHNP; Tim Langford, PharmD; Cat Livingston, MD; Eriko Onishi, MD; Eddie Saito, PharmD

**Staff Present:** Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Brandon Wells; Dee Weston, JD; Trevor Douglass, DC; Jennifer Bowen; Kyle Hamilton; Chris DeMars

**Audience:** Alice Wyse Jackson\*, Amgen; P Reeger Cortell\*, Southern Oregon Bariatric Center; LesleAnn Hayward Story\*, OHSU; Annie Griffin\*, US Citizen; Yolanda Clay\*, Obesity Action Coalition; Kristal Hartman\*, Obesity Action Coalition; Kat Khachatourian\*, Novo Nordisk; Josh Akers\*, Eli Lilly; Cody Gerber\*, Rhythm Pharmaceutical; Jamie Tobitt\*, Apellis Pharmaceuticals; Alexa Erickson, Umpqua Health; Bill Reid, Lilly; Brandie Feger, Advanced Health CCO; Bryan Armstrong, CareOregon; Carissa Kemp, American Diabetes Associations; Chris Ferrin, IHN; Drew Larson, OHSU Health; Jeff Forshey, Rhythm; Jeff White, Sumitomo; Jenny Todenhagen, Genentech; Kaitlyn Molina, Samaritan Health Plan; Lief Bruce, Novo Nordisk; Lisa Pulver, J&J; Lynda Finch, Biogen; Margaret Smith-Isa, OHA; Mark England, Mercer; Gary Parenteau, Dexcom; Matt Worthy, OHSU; Melissa Bailey Hall, Lilly; Melissa Abbott, Eisai; Norm Navarro, PHP; Sabrina Riggs, Novo Nordisk; Shauna Wick, Trillium Community Health Plan; Stacy Hamm, Genentech; Steve Hall, Genentech; Tiina Andrews, UHA; Katie Scheelar; Andi Stratton, Krystal Biotech; Reeger Cortell, FNP; Camille Kerr, Regeneron; Chrystal Jones; Baltazar Diaz, PacificSource Health Plans; Sehila Albeke, Ken Liu, Madrigal Pharma

**(\*) Provided verbal testimony**

---

## I. CALL TO ORDER

- A. Roll Call & Introductions
  - Called to order at approx. 1:05 p.m., introductions by Committee and staff
- B. Conflict of Interest Declaration – no new conflicts of interest were declared
- C. Approval of Agenda and February 2024 Minutes presented by Roger Citron, RPh  
**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**
- D. Department Update provided by Andrew Gibler, PharmD
- E. Legislative Update provided by Dee Weston, JD

---

## II. CONSENT AGENDA TOPICS

- A. Preferred Drug List (PDL): Insulin Literature Scan - Deferred to June P&T Meeting
- B. Vascular Endothelial Growth Factor (VEGF) Class Update & New Drug Evaluation (NDE)  
**Recommendation:**
  - No PDL recommendations based on clinical evidence
  - Evaluate costs in executive session
- C. PDL Old Business: Inhalers for Asthma and COPD Class Update  
**Recommendation:**
  - Evaluate costs in executive session
- D. Oncology Prior Authorization (PA) Updates  
**Recommendation:**
  - Add: Iwilfin™ (eflornithine); and Amtagvi™ (lifileucel) to Table 1 in the Oncology Agents PA criteria**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

---

## III. DUR NEW BUSINESS

- A. Orphan Drug Policy Updates: Sarah Servid, PharmD  
**Recommendation:**
  - Simplify PA criteria by linking to FDA labeling instead of including details in the PA
  - Update Table 1 in the Orphan Drugs PA criteria to support medically appropriate use of Adzynma (ADAMTS13, recombinant-krhn); Rethymic® (allogeneic processed thymus tissue-agdc); Filsuvev (birch triterpenes); Vyjuvek™ (beremagene geperpavec-svdt); Skysona® (elivaldogene autotemcel); and Recorlev® (levoketoconazole) based on FDA-approved label**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**
- B. Tepezza® (Teprotumumab) PA Update: Sara Fletcher, PharmD  
**Recommendation:**

- Update the PA criteria as proposed

**Public Comment:** Alice Wyse Jackson, Amgen

**ACTION:** Motion to approve, 2<sup>nd</sup>, all in favor

---

#### IV. PREFERRED DRUG LIST (PDL) NEW BUSINESS

**A. Drugs for Weight Loss Drug Effectiveness Review Project (DERP) Summary and Glucagon-like Peptide-1 (GLP1) Receptor Agonist (RA) Literature Scan:** Dee Weston & Kathy Sentena, PharmD

**Recommendations:**

- Recommend the OHA perform a budgetary analysis and identify a funding plan to consider opening coverage for weight management drugs
- Establish clinically appropriate minimum standards for required diet and lifestyle modifications
- Implement the proposed PA for coverage under the EPSDT
- No changes to the PDL for GLP1 and dual GLP1-GIP RAs are recommended based on review of the evidence
- Evaluate costs in the executive session

**Public Comment:** Reeger Cortell, S. Oregon Bariatric Center; LesleAnn Hayward Story, OHSU; Anne Griffin, US Citizen; Yolanda Clay, Obesity Action Coalition (OAC); Kristal Hartman, OAC; Kat Khachatourian, Novo Nordisk; Josh Akers, Eli Lilly; and Cody Gerber, Rhythm Pharmaceutical

**ACTION:** The Committee modified the proposed PA criteria for coverage under EPSDT down to 6 years of age and to add Orlistat to the tables

**Motion to approve, 2<sup>nd</sup>, all in favor**

**B. Drugs for Bowel Prep Class Review:** Deanna Moretz, PharmD

**Recommendations:**

- Add the "Bowel Preparations" class to the PDL and make at least one PEG product and one saline-laxative preferred
- Evaluate costs in executive session

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

**C. Antivirals for SARS-CoV2 Class Review:** Deanna Moretz, PharmD

**Recommendations:**

- Add the "COVID-19 Antivirals" class to the PDL and designate ritonavir-boosted nirmatrelvir and remdesivir preferred
- If approved by the FDA, make molnupiravir preferred on the PDL with age restrictions in patients <18 years old due to risk of adverse effects

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

**D. Syforve® (pegcetacoplan) & Izervay™ (avacincaptad) NDEs:** Dave Engen, PharmD

**Recommendations:**

- Add the “Ophthalmologic Complement Inhibitors” class to the PDL and designate pegcetacoplan and avacincaptad pegol as non-preferred

- Implement the proposed PA criteria to limit use to the FDA approved indications

**Public Comment:** Jamie Tobitt, Apellis Pharmaceuticals

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

**E. Phosphorus Binder Class Update and NDE:** Deanna Moretz, PharmD

**Recommendations:**

- Revise name of PDL class to “phosphate binders and absorption inhibitors”

- Maintain tenapanor as nonpreferred and amend PA criteria to allow coverage for clinically appropriate use as add-on therapy in hyperphosphatemia and CKD

- Evaluate costs in executive session

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

---

## V. EXECUTIVE SESSION

**Members Present:** Bridget Bradley, PharmD; Douglas Carr, MD; Russ Huffman, PMHNP; Tim Langford, PharmD; Cat Livingston, MD; Eriko Onishi, MD; Eddie Saito, PharmD

**Staff Present:** Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Andrew Gibler, PharmD; Lan Starkweather, PharmD; Brandon Wells

---

## VI. RECONVENE for PUBLIC RECOMMENDATIONS

**A. VEGF Class Update & NDE**

**Recommendation:** No PDL changes recommended

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

**B. Maintenance Inhalers for Asthma/COPD**

**Recommendations:** Make tiotropium capsules non-preferred

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

**C. Drugs for Weight Loss DERP Summary & GLP1 RA Lit Scan**

**Recommendations:** No PDL changes recommended



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy

Phone 503-947-5220 | Fax 503-947-1119

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

**D. Drugs for Bowel Prep Class Review**

**Recommendations:** Make Moviprep powder pack, SuTab tablet, and Clenpiq solution non-preferred; and make other bowel prep agents preferred

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

**E. Phosphorus Binder Class Update & NDE**

**Recommendation:** Make sevelamer HCl tablets non-preferred

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

---

**VII. ADJOURN**